Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alcidion GroupASX:ALC -3.13% Revenue per Share is A$0.03 as of Jun. 2026. The stock has 4 warning signs investors should review. Among 612 Healthcare Providers & Services companies, Alcidion Group ranks worse than 71.9% on this metric.
Alcidion Group's revenue per share for the
six
months ended in Jun. 2026 was A$0.01.
Alcidion Group's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.03.
Warning Sign:
Alcidion Group Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Alcidion Group was 29.20% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -1.10% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 0.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 21.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Alcidion Group's Revenue per Share or its related term are showing as below:
ASX:ALC'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.2 Med: 19 Max: 91.3
Current: -1.1
During the past 13 years, Alcidion Group's highest 3-Year average Revenue Per Share Growth Rate was 91.30% per year. The lowest was -7.20% per year. And the median was 19.00% per year.
ASX:ALC's 3-Year Revenue Growth Rate is ranked worse than 71.9% of 612
companies
in the Healthcare Providers & Services industry
Industry Median: 6.9
vs ASX:ALC: -1.10
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Alcidion Group Revenue per Share Related Terms
Alcidion Group Revenue per Share Historical Data
* Premium members only.
The historical data trend for Alcidion Group's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ALC vs VEEV, BTSG, HQY: Revenue per Share Comparison
For the Health Information Services subindustry, Alcidion Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcidion Group PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Alcidion Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Alcidion Group's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Alcidion Group's Revenue Per Share for the fiscal year that ended in Jun. 2026 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alcidion Group (ASX:ALC) has a Revenue per Share of A$0.03 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Alcidion Group and its competitors. According to the industry distribution chart, Alcidion Group ranks #440 out of 612 companies in the Healthcare Providers & Services industry, placing it in the top 71.9%.
Is Alcidion Group's Revenue per Share too high?
Alcidion Group's current Revenue per Share is A$0.03. Based on the distribution chart, Alcidion Group ranks #440 out of 612 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Alcidion Group's Revenue per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Alcidion Group ranks #440 out of 612 companies for Revenue per Share. This places Alcidion Group in the lower half of its industry. The industry median Revenue per Share is 6.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Healthcare Providers & Services company?
The median Revenue per Share among Healthcare Providers & Services companies is 6.90, based on 612 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Alcidion Group and its competitors. For the Healthcare Providers & Services industry, the median Revenue per Share is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcidion Group's current Revenue per Share is A$0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcidion Group stock overvalued right now?
Based on GuruFocus' analysis, Alcidion Group (ASX:ALC) is currently considered Fairly Valued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.09 — trading 7% below its estimated fair value. The current Revenue per Share is A$0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Alcidion Group (ASX:ALC), the current Revenue per Share is A$0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alcidion Group Ltd is a provider of intelligent informatics software. It offers a fully integrated digital patient care platform that includes a clinical decision support (CDS) system, Electronic Patient Record (EPR), and Patient Administration System (PAS). Alcidion is engaged in the development and licensing of its own healthcare software products (Miya Precision and its associated modules, including Miya Observations, Flow, Task Management and PAS), the reselling of healthcare software products from its strategic partners, and the delivery of product implementation, product support and maintenance, systems integration and data analysis services to healthcare customers in the United Kingdom, Australia, and New Zealand. The company generates maximum revenue from the United Kingdom.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ALC has been successfully added to your 
